Assessment of the TECOS study
Sitagliptin (trade names: Januvia, Xelevia) has been approved in Germany since March 2007 for the treatment of type 2 diabetes in adults who can't lower their blood sugar levels enough through exercise and diet alone and if certain other treatments aren't an option or aren't effective enough.
In 2015, a major study on sitagliptin involving more than 14,000 men and women with diabetes was published. This study is called the TECOS study. It looked into whether sitagliptin, when given in addition to standard diabetes treatment, influences the risk of cardiovascular disease such as heart attacks or strokes in adults who have diabetes and existing cardiovascular disease.
But according to the Institute for Quality and Efficiency in Health Care (IQWiG, Germany), the data from this study can't be used to draw any conclusions relevant to standard clinical practice in Germany. Analysis of the data showed that the study participants weren't given the standard diabetes treatment used in Germany.